VIDEO: Dosing evaluation trial aims to ‘broaden the label’ for sickle cell treatment

ByMatthew M. Heeney, MD

ByMarley V. Ghizzone

In this video, Matthew M. Heeney, MD, discussed results from the Solace-Kids trial, which was presented at ASH Annual Meeting and Exposition.

“This Solace-Kids trial is looking at crizanlizumab (Ryverna, Novartis) in younger age groups than it is currently approved for with an attempt to try to broaden the label,” said Heeney, associate chief of hematology at Boston’s Children's Hospital, director of the Sickle Cell Program in Dana-Farber/Boston Children’s Cancer and Blood Disorder Center and associate professor at Harvard Medical School.

Reference

Heeney MM, et al. Abstract 12. Presented at: ASH Annual Meeting & Exposition; Dec. 11-14, 2021; Atlanta.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interview

Disclosures: Heeney reports consulting for AstraZeneca, Cyclerion Therapeutics, Inc., Forma Therapeutics, Inc., Global Blood Therapeutics, Inc., Micelle BioPharma, Novartis Pharmaceuticals Corporation, Pfizer, and Vertex Pharmaceuticals, Inc./CRISPR Therapeutics; and receiving grant or research support from AstraZeneca, Global Blood Therapeutics and Novartis Pharmaceuticals Corporation.

Take Homes in Benign Hematology

Read more

VIDEO: Dosing evaluation trial aims to ‘broaden the label’ for sickle cell treatment

Reference

Related Content